Esperion Therapeutics (ESPR) Gains from Investment Securities (2012 - 2013)
Esperion Therapeutics (ESPR) posted Gains from Investment Securities of $2.5 million for Q2 2013, up 5959.52% on a QoQ basis from $42000.0 in Q1 2013.
Esperion Therapeutics (ESPR) Gains from Investment Securities (2012 - 2013) Analysis & Trends
Esperion Therapeutics' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $2.5 million for Q2 2013.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $2.5 million in Q2 2013, while the trailing twelve-month figure through Mar 2014 was $2.5 million (changed N/A YoY) and the FY2013 annual result came in at $2.6 million, up 8184.38% from the prior year.
- Gains from Investment Securities was $2.5 million for Q2 2013 at Esperion Therapeutics, up from $42000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $2.5 million in Q2 2013 and bottomed at -$32367.0 in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 2.55 Mn |
| Jun 30, 2013 | 2.55 Mn |
| Mar 31, 2013 | 42,000.00 |
| Mar 31, 2013 | 42,000.00 |
| Dec 31, 2012 | -32,367.00 |
| Dec 31, 2012 | -32,367.00 |